ID   RYR2_HUMAN              Reviewed;        4967 AA.
AC   Q92736; Q15411; Q546N8; Q5T3P2;
DT   26-SEP-2001, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 3.
DT   22-FEB-2023, entry version 230.
DE   RecName: Full=Ryanodine receptor 2;
DE            Short=RYR-2;
DE            Short=RyR2;
DE            Short=hRYR-2;
DE   AltName: Full=Cardiac muscle ryanodine receptor;
DE   AltName: Full=Cardiac muscle ryanodine receptor-calcium release channel;
DE   AltName: Full=Type 2 ryanodine receptor;
GN   Name=RYR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.
RC   TISSUE=Heart muscle;
RX   PubMed=8809036; DOI=10.1042/bj3180477;
RA   Tunwell R.E.A., Wickenden C., Bertrand B.M.A., Shevchenko V.I., Walsh M.B.,
RA   Allen P.D., Lai F.A.;
RT   "The human cardiac muscle ryanodine receptor-calcium release channel:
RT   identification, primary structure and topological analysis.";
RL   Biochem. J. 318:477-487(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARVD2 GLN-176; PRO-433;
RP   ILE-2386 AND MET-2504.
RX   PubMed=11159936; DOI=10.1093/hmg/10.3.189;
RA   Tiso N., Stephan D.A., Nava A., Bagattin A., Devaney J.M., Stanchi F.,
RA   Larderet G., Brahmbhatt B., Brown K., Bauce B., Muriago M., Basso C.,
RA   Thiene G., Danieli G.A., Rampazzo A.;
RT   "Identification of mutations in the cardiac ryanodine receptor gene in
RT   families affected with arrhythmogenic right ventricular cardiomyopathy type
RT   2 (ARVD2).";
RL   Hum. Mol. Genet. 10:189-194(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 9-87 AND 533-681, DEVELOPMENTAL STAGE, AND
RP   INDUCTION BY TGFB1.
RC   TISSUE=Heart muscle, and Myometrium;
RX   PubMed=9148749; DOI=10.1042/bj3220777;
RA   Awad S.S., Lamb H.K., Morgan J.M., Dunlop W., Gillespie J.I.;
RT   "Differential expression of ryanodine receptor RyR2 mRNA in the non-
RT   pregnant and pregnant human myometrium.";
RL   Biochem. J. 322:777-783(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4292-4479, AND TISSUE SPECIFICITY.
RC   TISSUE=Cerebellum, and Hippocampus;
RX   PubMed=9607712; DOI=10.1016/s0306-4522(97)00612-x;
RA   Martin C., Chapman K.E., Seckl J.R., Ashley R.H.;
RT   "Partial cloning and differential expression of ryanodine receptor/calcium-
RT   release channel genes in human tissues including the hippocampus and
RT   cerebellum.";
RL   Neuroscience 85:205-216(1998).
RN   [6]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH FKBP1B; PP1; PP2A AKAP6 AND PKA,
RP   INTERACTION WITH FKBP1B; PKA; PP1 AND PP2A, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, MUTAGENESIS OF SER-2808, AND PHOSPHORYLATION AT SER-2808.
RX   PubMed=10830164; DOI=10.1016/s0092-8674(00)80847-8;
RA   Marx S.O., Reiken S., Hisamatsu Y., Jayaraman T., Burkhoff D.,
RA   Rosemblit N., Marks A.R.;
RT   "PKA phosphorylation dissociates FKBP12.6 from the calcium release channel
RT   (ryanodine receptor): defective regulation in failing hearts.";
RL   Cell 101:365-376(2000).
RN   [7]
RP   INTERACTION WITH CALM AND S100A1.
RX   PubMed=18650434; DOI=10.1074/jbc.m804432200;
RA   Wright N.T., Prosser B.L., Varney K.M., Zimmer D.B., Schneider M.F.,
RA   Weber D.J.;
RT   "S100A1 and calmodulin compete for the same binding site on ryanodine
RT   receptor.";
RL   J. Biol. Chem. 283:26676-26683(2008).
RN   [8]
RP   FUNCTION, AND PHOSPHORYLATION AT SER-2808 AND SER-2814.
RX   PubMed=20056922; DOI=10.1161/circresaha.109.203836;
RA   Neef S., Dybkova N., Sossalla S., Ort K.R., Fluschnik N., Neumann K.,
RA   Seipelt R., Schondube F.A., Hasenfuss G., Maier L.S.;
RT   "CaMKII-dependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels
RT   in right atrial myocardium of patients with atrial fibrillation.";
RL   Circ. Res. 106:1134-1144(2010).
RN   [9]
RP   REVIEW.
RX   PubMed=11805843; DOI=10.1038/415198a;
RA   Bers D.M.;
RT   "Cardiac excitation-contraction coupling.";
RL   Nature 415:198-205(2002).
RN   [10]
RP   REVIEW.
RX   PubMed=19482609; DOI=10.2741/3591;
RA   Currie S.;
RT   "Cardiac ryanodine receptor phosphorylation by CaM Kinase II: keeping the
RT   balance right.";
RL   Front. Biosci. 14:5134-5156(2009).
RN   [11]
RP   REVIEW.
RX   PubMed=21472222; DOI=10.3892/mmr_00000240;
RA   Ozawa T.;
RT   "Modulation of ryanodine receptor Ca2+ channels.";
RL   Mol. Med. Report. 3:199-204(2010).
RN   [12]
RP   REVIEW.
RX   PubMed=20961976; DOI=10.1101/cshperspect.a003996;
RA   Lanner J.T., Georgiou D.K., Joshi A.D., Hamilton S.L.;
RT   "Ryanodine receptors: structure, expression, molecular details, and
RT   function in calcium release.";
RL   Cold Spring Harb. Perspect. Biol. 2:E3996-E3996(2010).
RN   [13] {ECO:0007744|PDB:4JKQ}
RP   X-RAY CRYSTALLOGRAPHY (2.39 ANGSTROMS) OF 1-606, AND CHARACTERIZATION OF
RP   VARIANT CPVT1 PHE-419.
RX   PubMed=25372681; DOI=10.1107/s1399004714020343;
RA   Borko L., Bauerova-Hlinkova V., Hostinova E., Gasperik J., Beck K.,
RA   Lai F.A., Zahradnikova A., Sevcik J.;
RT   "Structural insights into the human RyR2 N-terminal region involved in
RT   cardiac arrhythmias.";
RL   Acta Crystallogr. D 70:2897-2912(2014).
RN   [14]
RP   VARIANTS CPVT1 LEU-2246; SER-2474; LYS-4104 AND CYS-4497.
RX   PubMed=11208676; DOI=10.1161/01.cir.103.2.196;
RA   Priori S.G., Napolitano C., Tiso N., Memmi M., Vignati G., Bloise R.,
RA   Sorrentino V.V., Danieli G.A.;
RT   "Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie
RT   catecholaminergic polymorphic ventricular tachycardia.";
RL   Circulation 103:196-200(2001).
RN   [15]
RP   VARIANTS CPVT1 SER-2328; ARG-4201 AND PHE-4653, AND VARIANT ARG-2958.
RX   PubMed=11157710; DOI=10.1161/01.cir.103.4.485;
RA   Laitinen P.J., Brown K.M., Piippo K., Swan H., Devaney J.M., Brahmbhatt B.,
RA   Donarum E.A., Marino M., Tiso N., Viitasalo M., Toivonen L., Stephan D.A.,
RA   Kontula K.;
RT   "Mutations of the cardiac ryanodine receptor (RyR2) gene in familial
RT   polymorphic ventricular tachycardia.";
RL   Circulation 103:485-490(2001).
RN   [16]
RP   VARIANTS CPVT1 LEU-2246; ASP-2311; SER-2474; PHE-3778; SER-3946; SER-3946;
RP   LYS-4104; CYS-4497; ILE-4771; MET-4867; ASP-4895 AND LYS-4950, AND VARIANT
RP   VACRDS GLY-4860.
RX   PubMed=12093772; DOI=10.1161/01.cir.0000020013.73106.d8;
RA   Priori S.G., Napolitano C., Memmi M., Colombi B., Drago F., Gasparini M.,
RA   DeSimone L., Coltorti F., Bloise R., Keegan R., Cruz Filho F.E.S.,
RA   Vignati G., Benatar A., DeLogu A.;
RT   "Clinical and molecular characterization of patients with catecholaminergic
RT   polymorphic ventricular tachycardia.";
RL   Circulation 106:69-74(2002).
RN   [17]
RP   VARIANTS CPVT1 GLN-176; TRP-420; PRO-433; ILE-2386; CYS-2392 AND MET-2504.
RX   PubMed=12106942; DOI=10.1016/s0735-1097(02)01946-0;
RA   Bauce B., Rampazzo A., Basso C., Bagattin A., Daliento L., Tiso N.,
RA   Turrini P., Thiene G., Danieli G.A., Nava A.;
RT   "Screening for ryanodine receptor type 2 mutations in families with effort-
RT   induced polymorphic ventricular arrhythmias and sudden death: early
RT   diagnosis of asymptomatic carriers.";
RL   J. Am. Coll. Cardiol. 40:341-349(2002).
RN   [18]
RP   VARIANTS CPVT1 ILE-2306; LEU-4902 AND GLN-4959.
RX   PubMed=14571276; DOI=10.1038/sj.ejhg.5201061;
RA   Laitinen P.J., Swan H., Kontula K.;
RT   "Molecular genetics of exercise-induced polymorphic ventricular
RT   tachycardia: identification of three novel cardiac ryanodine receptor
RT   mutations and two common calsequestrin 2 amino-acid polymorphisms.";
RL   Eur. J. Hum. Genet. 11:888-891(2003).
RN   [19]
RP   VARIANTS CPVT1 SER-164; LEU-414; PHE-419; THR-2403; CYS-4499; THR-4510;
RP   ARG-4671 AND VAL-4848.
RX   PubMed=15466642; DOI=10.1161/01.cir.0000144471.98080.ca;
RA   Choi G., Kopplin L.J., Tester D.J., Will M.L., Haglund C.M., Ackerman M.J.;
RT   "Spectrum and frequency of cardiac channel defects in swimming-triggered
RT   arrhythmia syndromes.";
RL   Circulation 110:2119-2124(2004).
RN   [20]
RP   VARIANTS CPVT1 ILE-4504 AND ALA-4880.
RX   PubMed=15046072;
RA   Bagattin A., Veronese C., Rampazzo A., Danieli G.A.;
RT   "Gene symbol: RYR2. Disease: effort-induced polymorphic ventricular
RT   arrhythmias.";
RL   Hum. Genet. 114:404-404(2004).
RN   [21]
RP   VARIANTS CPVT1 PRO-2387 AND PRO-4607.
RX   PubMed=15046073;
RA   Bagattin A., Veronese C., Rampazzo A., Danieli G.A.;
RT   "Gene symbol: RYR2. Disease: effort-induced polymorphic ventricular
RT   arrhythmias.";
RL   Hum. Genet. 114:405-405(2004).
RN   [22]
RP   VARIANTS CPVT1 TRP-420; LEU-2246; SER-4097; LYS-4146; PRO-4158 AND
RP   CYS-4497.
RX   PubMed=15544015; DOI=10.4065/79.11.1380;
RA   Tester D.J., Spoon D.B., Valdivia H.H., Makielski J.C., Ackerman M.J.;
RT   "Targeted mutational analysis of the RyR2-encoded cardiac ryanodine
RT   receptor in sudden unexplained death: a molecular autopsy of 49 medical
RT   examiner/coroner's cases.";
RL   Mayo Clin. Proc. 79:1380-1384(2004).
RN   [23]
RP   VARIANTS CPVT1 GLN-176; LEU-414; PHE-419; ALA-466; THR-2403; PHE-3800;
RP   THR-4124; CYS-4499; THR-4510; THR-4556; VAL-4848 AND GLN-4959.
RX   PubMed=16188589; DOI=10.1016/j.hrthm.2005.07.012;
RA   Tester D.J., Kopplin L.J., Will M.L., Ackerman M.J.;
RT   "Spectrum and prevalence of cardiac ryanodine receptor (RyR2) mutations in
RT   a cohort of unrelated patients referred explicitly for long QT syndrome
RT   genetic testing.";
RL   Heart Rhythm 2:1099-1105(2005).
RN   [24]
RP   VARIANT GLU-4955.
RX   PubMed=25356899; DOI=10.1371/journal.pgen.1004772;
RA   Hamdan F.F., Srour M., Capo-Chichi J.M., Daoud H., Nassif C., Patry L.,
RA   Massicotte C., Ambalavanan A., Spiegelman D., Diallo O., Henrion E.,
RA   Dionne-Laporte A., Fougerat A., Pshezhetsky A.V., Venkateswaran S.,
RA   Rouleau G.A., Michaud J.L.;
RT   "De novo mutations in moderate or severe intellectual disability.";
RL   PLoS Genet. 10:E1004772-E1004772(2014).
RN   [25]
RP   CHARACTERIZATION OF VARIANT VACRDS GLY-4860.
RX   PubMed=17984046; DOI=10.1073/pnas.0706573104;
RA   Jiang D., Chen W., Wang R., Zhang L., Chen S.R.W.;
RT   "Loss of luminal Ca(2+) activation in the cardiac ryanodine receptor is
RT   associated with ventricular fibrillation and sudden death.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:18309-18314(2007).
RN   [26]
RP   VARIANT CPVT1 PRO-4159.
RX   PubMed=24793461; DOI=10.1016/j.hrthm.2014.04.037;
RA   Di Pino A., Caruso E., Costanzo L., Guccione P.;
RT   "A novel RyR2 mutation in a 2-year-old baby presenting with atrial
RT   fibrillation, atrial flutter, and atrial ectopic tachycardia.";
RL   Heart Rhythm 11:1480-1483(2014).
RN   [27]
RP   VARIANT ASP-29.
RX   PubMed=25463374; DOI=10.1016/j.ijcard.2014.11.119;
RA   Cheung J.W., Meli A.C., Xie W., Mittal S., Reiken S., Wronska A., Xu L.,
RA   Steinberg J.S., Markowitz S.M., Iwai S., Lacampagne A., Lerman B.B.,
RA   Marks A.R.;
RT   "Short-coupled polymorphic ventricular tachycardia at rest linked to a
RT   novel ryanodine receptor (RyR2) mutation: leaky RyR2 channels under non-
RT   stress conditions.";
RL   Int. J. Cardiol. 180:228-236(2015).
RN   [28]
RP   CHARACTERIZATION OF VARIANT ASP-29.
RX   PubMed=26405799; DOI=10.1371/journal.pone.0139058;
RA   Xiao Z., Guo W., Yuen S.M., Wang R., Zhang L., Van Petegem F., Chen S.R.;
RT   "The H29D nutation does not enhance cytosolic Ca2+ activation of the
RT   cardiac ryanodine receptor.";
RL   PLoS ONE 10:E0139058-E0139058(2015).
RN   [29]
RP   CHARACTERIZATION OF VARIANTS CVPT1 SER-3946; THR-4124; PRO-4158 AND
RP   PRO-4159, MUTAGENESIS OF GLY-3946; MET-3978 AND HIS-4108, AND FUNCTION.
RX   PubMed=27733687; DOI=10.1074/jbc.m116.756528;
RA   Xiao Z., Guo W., Sun B., Hunt D.J., Wei J., Liu Y., Wang Y., Wang R.,
RA   Jones P.P., Back T.G., Chen S.R.;
RT   "Enhanced cytosolic Ca2+ activation underlies a common defect of central
RT   domain cardiac ryanodine receptor mutations linked to arrhythmias.";
RL   J. Biol. Chem. 291:24528-24537(2016).
RN   [30]
RP   VARIANTS VACRDS LEU-3774; ILE-4196; ALA-4646; GLY-4860 AND PHE-4938,
RP   INVOLVEMENT IN VACRDS, CHARACTERIZATION OF VARIANTS VACRDS LEU-3774;
RP   ILE-4196; ALA-4646; GLY-4860 AND PHE-4938, MUTAGENESIS OF ILE-3995;
RP   ASP-4112; ILE-4855 AND GLN-4879, AND FUNCTION.
RX   PubMed=33536282; DOI=10.1126/scitranslmed.aba7287;
RA   Sun B., Yao J., Ni M., Wei J., Zhong X., Guo W., Zhang L., Wang R.,
RA   Belke D., Chen Y.X., Lieve K.V.V., Broendberg A.K., Roston T.M.,
RA   Blankoff I., Kammeraad J.A., von Alvensleben J.C., Lazarte J.,
RA   Vallmitjana A., Bohne L.J., Rose R.A., Benitez R., Hove-Madsen L.,
RA   Napolitano C., Hegele R.A., Fill M., Sanatani S., Wilde A.A.M.,
RA   Roberts J.D., Priori S.G., Jensen H.K., Chen S.R.W.;
RT   "Cardiac ryanodine receptor calcium release deficiency syndrome.";
RL   Sci. Transl. Med. 13:0-0(2021).
CC   -!- FUNCTION: Calcium channel that mediates the release of Ca(2+) from the
CC       sarcoplasmic reticulum into the cytoplasm and thereby plays a key role
CC       in triggering cardiac muscle contraction. Aberrant channel activation
CC       can lead to cardiac arrhythmia. In cardiac myocytes, calcium release is
CC       triggered by increased Ca(2+) levels due to activation of the L-type
CC       calcium channel CACNA1C. The calcium channel activity is modulated by
CC       formation of heterotetramers with RYR3. Required for cellular calcium
CC       ion homeostasis. Required for embryonic heart development.
CC       {ECO:0000269|PubMed:10830164, ECO:0000269|PubMed:20056922,
CC       ECO:0000269|PubMed:27733687, ECO:0000269|PubMed:33536282}.
CC   -!- ACTIVITY REGULATION: Channel activity is modulated by the alkaloid
CC       ryanodine that binds to the open Ca-release channel with high affinity.
CC       At low concentrations, ryanodine maintains the channel in an open
CC       conformation. High ryanodine concentrations inhibit channel activity.
CC       Channel activity is regulated by calmodulin (CALM). The calcium release
CC       is activated by increased cytoplasmic calcium levels, by nitric oxyde
CC       (NO), caffeine and ATP. Channel activity is inhibited by magnesium
CC       ions, possibly by competition for calcium binding sites.
CC       {ECO:0000250|UniProtKB:P11716}.
CC   -!- SUBUNIT: Homotetramer. Can also form heterotetramers with RYR1 and RYR3
CC       (By similarity). Interacts with FKBP1A and FKBP1B; these interactions
CC       may stabilize the channel in its closed state and prevent Ca(2+) leaks.
CC       Interacts with CALM and S100A1; these interactions regulate channel
CC       activity. Identified in a complex composed of RYR2, FKBP1B, PKA
CC       catalytic subunit, PRKAR2A, AKAP6, and the protein phosphatases PP2A
CC       and PP1. Interacts directly with FKBP1B, PKA, PP1 and PP2A. Interacts
CC       with SELENON (By similarity). In cardiac muscles, identified in a
CC       complex, composed of FSD2, CMYA5 and RYR2 (By similarity).
CC       {ECO:0000250|UniProtKB:E9Q401, ECO:0000250|UniProtKB:P30957,
CC       ECO:0000269|PubMed:10830164, ECO:0000269|PubMed:18650434}.
CC   -!- INTERACTION:
CC       Q92736; P62942: FKBP1A; NbExp=2; IntAct=EBI-1170425, EBI-1027571;
CC       Q92736; P68106: FKBP1B; NbExp=5; IntAct=EBI-1170425, EBI-6693977;
CC       Q92736; Q00987: MDM2; NbExp=2; IntAct=EBI-1170425, EBI-389668;
CC   -!- SUBCELLULAR LOCATION: Sarcoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:10830164}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:10830164}. Membrane {ECO:0000305|PubMed:10830164};
CC       Multi-pass membrane protein {ECO:0000305|PubMed:10830164}. Sarcoplasmic
CC       reticulum {ECO:0000250|UniProtKB:P30957}. Note=The number of predicted
CC       transmembrane domains varies between orthologs, but both N-terminus and
CC       C-terminus seem to be cytoplasmic. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q92736-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q92736-2; Sequence=VSP_005953;
CC   -!- TISSUE SPECIFICITY: Detected in heart muscle (at protein level). Heart
CC       muscle, brain (cerebellum and hippocampus) and placenta.
CC       {ECO:0000269|PubMed:10830164, ECO:0000269|PubMed:9607712}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in myometrium during pregnancy.
CC       {ECO:0000269|PubMed:9148749}.
CC   -!- INDUCTION: By TGFB1. {ECO:0000269|PubMed:9148749}.
CC   -!- DOMAIN: The calcium release channel activity resides in the C-terminal
CC       region while the remaining part of the protein resides in the
CC       cytoplasm. {ECO:0000305}.
CC   -!- PTM: Channel activity is modulated by phosphorylation. Phosphorylation
CC       at Ser-2808 and Ser-2814 increases the open probability of the calcium
CC       channel. Phosphorylation is increased in failing heart, leading to
CC       calcium leaks and increased cytoplasmic Ca(2+) levels.
CC       {ECO:0000269|PubMed:10830164, ECO:0000269|PubMed:20056922}.
CC   -!- PTM: Phosphorylation at Ser-2031 by PKA enhances the response to
CC       lumenal calcium. {ECO:0000250}.
CC   -!- DISEASE: Arrhythmogenic right ventricular dysplasia, familial, 2
CC       (ARVD2) [MIM:600996]: A congenital heart disease characterized by
CC       infiltration of adipose and fibrous tissue into the right ventricle and
CC       loss of myocardial cells, resulting in ventricular and supraventricular
CC       arrhythmias. {ECO:0000269|PubMed:11159936}. Note=The disease is caused
CC       by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Ventricular tachycardia, catecholaminergic polymorphic, 1,
CC       with or without atrial dysfunction and/or dilated cardiomyopathy
CC       (CPVT1) [MIM:604772]: An arrhythmogenic disorder characterized by
CC       stress-induced, bidirectional ventricular tachycardia that may
CC       degenerate into cardiac arrest and cause sudden death. Patients present
CC       with recurrent syncope, seizures, or sudden death after physical
CC       activity or emotional stress. CPVT1 inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:11157710, ECO:0000269|PubMed:11208676,
CC       ECO:0000269|PubMed:12093772, ECO:0000269|PubMed:12106942,
CC       ECO:0000269|PubMed:14571276, ECO:0000269|PubMed:15046072,
CC       ECO:0000269|PubMed:15046073, ECO:0000269|PubMed:15466642,
CC       ECO:0000269|PubMed:15544015, ECO:0000269|PubMed:16188589,
CC       ECO:0000269|PubMed:24793461, ECO:0000269|PubMed:25372681,
CC       ECO:0000269|PubMed:27733687}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Ventricular arrhythmias due to cardiac ryanodine receptor
CC       calcium release deficiency syndrome (VACRDS) [MIM:115000]: An autosomal
CC       dominant arrhythmogenic disorder characterized by syncope, cardiac
CC       arrest and/or sudden unexpected death, often in association with
CC       physical exertion or acute emotional stress. Patients who survive
CC       manifest polymorphic ventricular tachycardia and ventricular
CC       fibrillation. Unlike typical catecholaminergic ventricular tachycardia,
CC       arrhythmias are not reproducible on exercise stress testing or
CC       adrenaline challenge. {ECO:0000269|PubMed:12093772,
CC       ECO:0000269|PubMed:17984046, ECO:0000269|PubMed:33536282}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the ryanodine receptor (TC 1.A.3.1) family. RYR2
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAH71369.1; Type=Miscellaneous discrepancy; Note=Erroneous gene model prediction.; Evidence={ECO:0000305};
CC       Sequence=CAH71393.1; Type=Miscellaneous discrepancy; Note=Erroneous gene model prediction.; Evidence={ECO:0000305};
CC       Sequence=CAH73918.1; Type=Miscellaneous discrepancy; Note=Erroneous gene model prediction.; Evidence={ECO:0000305};
CC       Sequence=CAI14440.1; Type=Miscellaneous discrepancy; Note=Erroneous gene model prediction.; Evidence={ECO:0000305};
CC       Sequence=CAI15350.1; Type=Miscellaneous discrepancy; Note=Erroneous gene model prediction.; Evidence={ECO:0000305};
CC       Sequence=CAI15936.1; Type=Miscellaneous discrepancy; Note=Erroneous gene model prediction.; Evidence={ECO:0000305};
CC       Sequence=CAI22065.1; Type=Miscellaneous discrepancy; Note=Erroneous gene model prediction.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Ryanodine receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Ryanodine_receptor";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=RYR2 entry;
CC       URL="https://en.wikipedia.org/wiki/RYR2";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X98330; CAA66975.1; -; mRNA.
DR   EMBL; AJ300340; CAC18855.1; -; Genomic_DNA.
DR   EMBL; AJ300341; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300342; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300343; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300347; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300349; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300351; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300353; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300355; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300364; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300363; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300362; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300361; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300360; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300359; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300358; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300357; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300356; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300373; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300372; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300371; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300370; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300369; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300368; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300367; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300366; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300365; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300382; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300381; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300380; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300379; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300378; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300377; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300376; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300375; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300374; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300399; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300398; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300397; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300396; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300395; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300394; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300393; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300392; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300391; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300416; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300415; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300414; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300413; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300412; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300411; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300410; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300409; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300408; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300433; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300432; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300431; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300430; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300429; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300428; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300427; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300426; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300425; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300444; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300443; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300442; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300441; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300440; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300439; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300438; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300437; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300436; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300435; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300434; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300424; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300423; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300422; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300421; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300420; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300419; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300418; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300417; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300407; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300406; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300405; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300404; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300403; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300402; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300401; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300400; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300390; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300389; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300388; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300387; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300386; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300385; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300384; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300383; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300354; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300352; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300350; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300348; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300346; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300345; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AJ300344; CAC18855.1; JOINED; Genomic_DNA.
DR   EMBL; AL365332; CAH71369.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL356773; CAH71369.1; JOINED; Genomic_DNA.
DR   EMBL; AL359924; CAH71369.1; JOINED; Genomic_DNA.
DR   EMBL; AL391809; CAH71369.1; JOINED; Genomic_DNA.
DR   EMBL; AL442065; CAH71369.1; JOINED; Genomic_DNA.
DR   EMBL; AL445473; CAH71369.1; JOINED; Genomic_DNA.
DR   EMBL; AL513130; CAH71369.1; JOINED; Genomic_DNA.
DR   EMBL; AL445473; CAH71393.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL356773; CAH71393.1; JOINED; Genomic_DNA.
DR   EMBL; AL359924; CAH71393.1; JOINED; Genomic_DNA.
DR   EMBL; AL365332; CAH71393.1; JOINED; Genomic_DNA.
DR   EMBL; AL391809; CAH71393.1; JOINED; Genomic_DNA.
DR   EMBL; AL442065; CAH71393.1; JOINED; Genomic_DNA.
DR   EMBL; AL513130; CAH71393.1; JOINED; Genomic_DNA.
DR   EMBL; AL356773; CAH73918.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL359924; CAH73918.1; JOINED; Genomic_DNA.
DR   EMBL; AL365332; CAH73918.1; JOINED; Genomic_DNA.
DR   EMBL; AL391809; CAH73918.1; JOINED; Genomic_DNA.
DR   EMBL; AL442065; CAH73918.1; JOINED; Genomic_DNA.
DR   EMBL; AL445473; CAH73918.1; JOINED; Genomic_DNA.
DR   EMBL; AL513130; CAH73918.1; JOINED; Genomic_DNA.
DR   EMBL; AL391809; CAI14440.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL356773; CAI14440.1; JOINED; Genomic_DNA.
DR   EMBL; AL359924; CAI14440.1; JOINED; Genomic_DNA.
DR   EMBL; AL365332; CAI14440.1; JOINED; Genomic_DNA.
DR   EMBL; AL442065; CAI14440.1; JOINED; Genomic_DNA.
DR   EMBL; AL445473; CAI14440.1; JOINED; Genomic_DNA.
DR   EMBL; AL513130; CAI14440.1; JOINED; Genomic_DNA.
DR   EMBL; AL442065; CAI15350.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL356773; CAI15350.1; JOINED; Genomic_DNA.
DR   EMBL; AL359924; CAI15350.1; JOINED; Genomic_DNA.
DR   EMBL; AL365332; CAI15350.1; JOINED; Genomic_DNA.
DR   EMBL; AL391809; CAI15350.1; JOINED; Genomic_DNA.
DR   EMBL; AL445473; CAI15350.1; JOINED; Genomic_DNA.
DR   EMBL; AL513130; CAI15350.1; JOINED; Genomic_DNA.
DR   EMBL; AL513130; CAI15936.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL356773; CAI15936.1; JOINED; Genomic_DNA.
DR   EMBL; AL359924; CAI15936.1; JOINED; Genomic_DNA.
DR   EMBL; AL365332; CAI15936.1; JOINED; Genomic_DNA.
DR   EMBL; AL391809; CAI15936.1; JOINED; Genomic_DNA.
DR   EMBL; AL442065; CAI15936.1; JOINED; Genomic_DNA.
DR   EMBL; AL445473; CAI15936.1; JOINED; Genomic_DNA.
DR   EMBL; AL359924; CAI22065.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL356773; CAI22065.1; JOINED; Genomic_DNA.
DR   EMBL; AL365332; CAI22065.1; JOINED; Genomic_DNA.
DR   EMBL; AL391809; CAI22065.1; JOINED; Genomic_DNA.
DR   EMBL; AL442065; CAI22065.1; JOINED; Genomic_DNA.
DR   EMBL; AL445473; CAI22065.1; JOINED; Genomic_DNA.
DR   EMBL; AL513130; CAI22065.1; JOINED; Genomic_DNA.
DR   EMBL; Y08218; CAA69395.1; -; mRNA.
DR   EMBL; X91869; CAA62975.1; -; mRNA.
DR   EMBL; AJ002511; CAA05502.1; -; mRNA.
DR   CCDS; CCDS55691.1; -. [Q92736-1]
DR   PIR; S72269; S72269.
DR   RefSeq; NP_001026.2; NM_001035.2. [Q92736-1]
DR   RefSeq; XP_006711868.1; XM_006711805.3. [Q92736-2]
DR   PDB; 4JKQ; X-ray; 2.39 A; A=1-606.
DR   PDB; 6Y4O; X-ray; 1.84 A; B=3581-3607.
DR   PDB; 6Y4P; X-ray; 2.13 A; B=3581-3607.
DR   PDB; 7KL5; X-ray; 1.65 A; B=4246-4275.
DR   PDB; 7U9Q; EM; 3.11 A; A/B/C/D=1-4967.
DR   PDB; 7U9R; EM; 3.69 A; A/B/C/D=1-4967.
DR   PDB; 7U9T; EM; 2.68 A; A/B/C/D=1-4967.
DR   PDB; 7U9X; EM; 2.58 A; A/B/C/D=1-4967.
DR   PDB; 7U9Z; EM; 3.29 A; A/B/C/D=1-4967.
DR   PDB; 7UA1; EM; 2.99 A; A/B/C/D=1-4967.
DR   PDB; 7UA3; EM; 2.97 A; A/B/C/D=1-4967.
DR   PDB; 7UA4; EM; 2.93 A; A/B/C/D=1-4967.
DR   PDB; 7UA5; EM; 2.83 A; A/B/C/D=1-4967.
DR   PDB; 7UA9; EM; 3.59 A; A/B/C/D=1-4967.
DR   PDBsum; 4JKQ; -.
DR   PDBsum; 6Y4O; -.
DR   PDBsum; 6Y4P; -.
DR   PDBsum; 7KL5; -.
DR   PDBsum; 7U9Q; -.
DR   PDBsum; 7U9R; -.
DR   PDBsum; 7U9T; -.
DR   PDBsum; 7U9X; -.
DR   PDBsum; 7U9Z; -.
DR   PDBsum; 7UA1; -.
DR   PDBsum; 7UA3; -.
DR   PDBsum; 7UA4; -.
DR   PDBsum; 7UA5; -.
DR   PDBsum; 7UA9; -.
DR   BMRB; Q92736; -.
DR   SMR; Q92736; -.
DR   BioGRID; 112174; 40.
DR   ComplexPortal; CPX-3156; Ryanodine 2 complex.
DR   DIP; DIP-38325N; -.
DR   IntAct; Q92736; 15.
DR   MINT; Q92736; -.
DR   STRING; 9606.ENSP00000355533; -.
DR   ChEMBL; CHEMBL4403; -.
DR   DrugBank; DB11093; Calcium citrate.
DR   DrugBank; DB11348; Calcium Phosphate.
DR   DrugBank; DB14481; Calcium phosphate dihydrate.
DR   DrugBank; DB01195; Flecainide.
DR   DrugBank; DB09085; Tetracaine.
DR   DrugCentral; Q92736; -.
DR   GuidetoPHARMACOLOGY; 748; -.
DR   TCDB; 1.A.3.1.1; the ryanodine-inositol 1,4,5-triphosphate receptor ca(2+) channel (rir-cac) family.
DR   CarbonylDB; Q92736; -.
DR   GlyCosmos; Q92736; 1 site, 1 glycan.
DR   GlyGen; Q92736; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q92736; -.
DR   PhosphoSitePlus; Q92736; -.
DR   SwissPalm; Q92736; -.
DR   BioMuta; RYR2; -.
DR   DMDM; 308153558; -.
DR   EPD; Q92736; -.
DR   jPOST; Q92736; -.
DR   MassIVE; Q92736; -.
DR   MaxQB; Q92736; -.
DR   PaxDb; Q92736; -.
DR   PeptideAtlas; Q92736; -.
DR   ProteomicsDB; 75431; -. [Q92736-1]
DR   ProteomicsDB; 75432; -. [Q92736-2]
DR   Antibodypedia; 3476; 246 antibodies from 31 providers.
DR   DNASU; 6262; -.
DR   Ensembl; ENST00000366574.7; ENSP00000355533.2; ENSG00000198626.18. [Q92736-1]
DR   GeneID; 6262; -.
DR   KEGG; hsa:6262; -.
DR   MANE-Select; ENST00000366574.7; ENSP00000355533.2; NM_001035.3; NP_001026.2.
DR   UCSC; uc001hyl.2; human. [Q92736-1]
DR   AGR; HGNC:10484; -.
DR   CTD; 6262; -.
DR   DisGeNET; 6262; -.
DR   GeneCards; RYR2; -.
DR   GeneReviews; RYR2; -.
DR   HGNC; HGNC:10484; RYR2.
DR   HPA; ENSG00000198626; Tissue enriched (heart).
DR   MalaCards; RYR2; -.
DR   MIM; 115000; phenotype.
DR   MIM; 180902; gene.
DR   MIM; 600996; phenotype.
DR   MIM; 604772; phenotype.
DR   neXtProt; NX_Q92736; -.
DR   OpenTargets; ENSG00000198626; -.
DR   Orphanet; 3286; Catecholaminergic polymorphic ventricular tachycardia.
DR   Orphanet; 293899; Familial isolated arrhythmogenic ventricular dysplasia, biventricular form.
DR   Orphanet; 293888; Familial isolated arrhythmogenic ventricular dysplasia, left dominant form.
DR   Orphanet; 293910; Familial isolated arrhythmogenic ventricular dysplasia, right dominant form.
DR   VEuPathDB; HostDB:ENSG00000198626; -.
DR   eggNOG; KOG2243; Eukaryota.
DR   GeneTree; ENSGT00940000154906; -.
DR   HOGENOM; CLU_000040_2_0_1; -.
DR   InParanoid; Q92736; -.
DR   OMA; HYEDTSD; -.
DR   OrthoDB; 3144451at2759; -.
DR   PhylomeDB; Q92736; -.
DR   TreeFam; TF315244; -.
DR   PathwayCommons; Q92736; -.
DR   Reactome; R-HSA-2672351; Stimuli-sensing channels.
DR   Reactome; R-HSA-5578775; Ion homeostasis.
DR   SignaLink; Q92736; -.
DR   SIGNOR; Q92736; -.
DR   BioGRID-ORCS; 6262; 7 hits in 1152 CRISPR screens.
DR   ChiTaRS; RYR2; human.
DR   GeneWiki; Ryanodine_receptor_2; -.
DR   GenomeRNAi; 6262; -.
DR   Pharos; Q92736; Tclin.
DR   PRO; PR:Q92736; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q92736; protein.
DR   Bgee; ENSG00000198626; Expressed in heart right ventricle and 137 other tissues.
DR   ExpressionAtlas; Q92736; baseline and differential.
DR   Genevisible; Q92736; HS.
DR   GO; GO:0034704; C:calcium channel complex; IDA:BHF-UCL.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IBA:GO_Central.
DR   GO; GO:0014701; C:junctional sarcoplasmic reticulum membrane; TAS:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0042383; C:sarcolemma; IBA:GO_Central.
DR   GO; GO:0016529; C:sarcoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; ISS:BHF-UCL.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IBA:GO_Central.
DR   GO; GO:0030018; C:Z disc; IDA:BHF-UCL.
DR   GO; GO:0005262; F:calcium channel activity; ISS:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IBA:GO_Central.
DR   GO; GO:0048763; F:calcium-induced calcium release activity; IDA:BHF-UCL.
DR   GO; GO:0015278; F:calcium-release channel activity; IDA:BHF-UCL.
DR   GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:BHF-UCL.
DR   GO; GO:0034236; F:protein kinase A catalytic subunit binding; IDA:BHF-UCL.
DR   GO; GO:0034237; F:protein kinase A regulatory subunit binding; IDA:BHF-UCL.
DR   GO; GO:0043621; F:protein self-association; IEA:Ensembl.
DR   GO; GO:0005219; F:ryanodine-sensitive calcium-release channel activity; IDA:BHF-UCL.
DR   GO; GO:0043924; F:suramin binding; IMP:BHF-UCL.
DR   GO; GO:0044325; F:transmembrane transporter binding; ISS:BHF-UCL.
DR   GO; GO:0006816; P:calcium ion transport; IDA:BHF-UCL.
DR   GO; GO:0060402; P:calcium ion transport into cytosol; IDA:BHF-UCL.
DR   GO; GO:0019722; P:calcium-mediated signaling; ISS:UniProtKB.
DR   GO; GO:0035584; P:calcium-mediated signaling using intracellular calcium source; IDA:BHF-UCL.
DR   GO; GO:0060048; P:cardiac muscle contraction; IMP:BHF-UCL.
DR   GO; GO:0003300; P:cardiac muscle hypertrophy; ISS:BHF-UCL.
DR   GO; GO:0086064; P:cell communication by electrical coupling involved in cardiac conduction; IC:BHF-UCL.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; ISS:UniProtKB.
DR   GO; GO:0071313; P:cellular response to caffeine; IDA:BHF-UCL.
DR   GO; GO:0071872; P:cellular response to epinephrine stimulus; ISS:BHF-UCL.
DR   GO; GO:0005513; P:detection of calcium ion; IDA:BHF-UCL.
DR   GO; GO:0003143; P:embryonic heart tube morphogenesis; ISS:UniProtKB.
DR   GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl.
DR   GO; GO:0072599; P:establishment of protein localization to endoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0003220; P:left ventricular cardiac muscle tissue morphogenesis; ISS:BHF-UCL.
DR   GO; GO:1901896; P:positive regulation of ATPase-coupled calcium transmembrane transporter activity; IDA:BHF-UCL.
DR   GO; GO:0010460; P:positive regulation of heart rate; ISS:BHF-UCL.
DR   GO; GO:0051284; P:positive regulation of sequestering of calcium ion; IDA:BHF-UCL.
DR   GO; GO:0098735; P:positive regulation of the force of heart contraction; IMP:BHF-UCL.
DR   GO; GO:0086029; P:Purkinje myocyte to ventricular cardiac muscle cell signaling; ISS:BHF-UCL.
DR   GO; GO:0098910; P:regulation of atrial cardiac muscle cell action potential; IMP:BHF-UCL.
DR   GO; GO:0098904; P:regulation of AV node cell action potential; IMP:BHF-UCL.
DR   GO; GO:0055117; P:regulation of cardiac muscle contraction; IMP:BHF-UCL.
DR   GO; GO:0010882; P:regulation of cardiac muscle contraction by calcium ion signaling; IMP:BHF-UCL.
DR   GO; GO:0010881; P:regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion; ISS:BHF-UCL.
DR   GO; GO:0051480; P:regulation of cytosolic calcium ion concentration; ISS:BHF-UCL.
DR   GO; GO:0002027; P:regulation of heart rate; IMP:BHF-UCL.
DR   GO; GO:0098907; P:regulation of SA node cell action potential; IMP:BHF-UCL.
DR   GO; GO:0098911; P:regulation of ventricular cardiac muscle cell action potential; IMP:BHF-UCL.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IDA:BHF-UCL.
DR   GO; GO:0014808; P:release of sequestered calcium ion into cytosol by sarcoplasmic reticulum; IMP:BHF-UCL.
DR   GO; GO:0031000; P:response to caffeine; IDA:BHF-UCL.
DR   GO; GO:0001666; P:response to hypoxia; ISS:BHF-UCL.
DR   GO; GO:0014850; P:response to muscle activity; IMP:BHF-UCL.
DR   GO; GO:0035994; P:response to muscle stretch; IMP:BHF-UCL.
DR   GO; GO:0051775; P:response to redox state; IDA:BHF-UCL.
DR   GO; GO:0070296; P:sarcoplasmic reticulum calcium ion transport; TAS:BHF-UCL.
DR   GO; GO:0097050; P:type B pancreatic cell apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0086005; P:ventricular cardiac muscle cell action potential; ISS:BHF-UCL.
DR   CDD; cd12877; SPRY1_RyR; 1.
DR   CDD; cd12878; SPRY2_RyR; 1.
DR   CDD; cd12879; SPRY3_RyR; 1.
DR   Gene3D; 1.10.287.70; -; 1.
DR   Gene3D; 1.10.490.160; -; 3.
DR   Gene3D; 2.60.120.920; -; 3.
DR   Gene3D; 2.80.10.50; -; 2.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   Gene3D; 1.25.10.30; IP3 receptor type 1 binding core, RIH domain; 1.
DR   InterPro; IPR001870; B30.2/SPRY.
DR   InterPro; IPR043136; B30.2/SPRY_sf.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR014821; Ins145_P3_rcpt.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR036300; MIR_dom_sf.
DR   InterPro; IPR016093; MIR_motif.
DR   InterPro; IPR013662; RIH_assoc-dom.
DR   InterPro; IPR000699; RIH_dom.
DR   InterPro; IPR013333; Ryan_recept.
DR   InterPro; IPR015925; Ryanodine_IP3_receptor.
DR   InterPro; IPR003032; Ryanodine_rcpt.
DR   InterPro; IPR009460; Ryanrecept_TM4-6.
DR   InterPro; IPR035910; RyR/IP3R_RIH_dom_sf.
DR   InterPro; IPR035761; SPRY1_RyR.
DR   InterPro; IPR035764; SPRY2_RyR.
DR   InterPro; IPR035762; SPRY3_RyR.
DR   InterPro; IPR003877; SPRY_dom.
DR   PANTHER; PTHR46399; B30.2/SPRY DOMAIN-CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR46399:SF7; RYANODINE RECEPTOR 2; 1.
DR   Pfam; PF08709; Ins145_P3_rec; 1.
DR   Pfam; PF00520; Ion_trans; 1.
DR   Pfam; PF02815; MIR; 1.
DR   Pfam; PF08454; RIH_assoc; 1.
DR   Pfam; PF06459; RR_TM4-6; 1.
DR   Pfam; PF01365; RYDR_ITPR; 2.
DR   Pfam; PF02026; RyR; 4.
DR   Pfam; PF00622; SPRY; 3.
DR   PRINTS; PR00795; RYANODINER.
DR   SMART; SM00472; MIR; 4.
DR   SMART; SM00449; SPRY; 3.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 2.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   SUPFAM; SSF100909; IP3 receptor type 1 binding core, domain 2; 2.
DR   SUPFAM; SSF82109; MIR domain; 2.
DR   PROSITE; PS50188; B302_SPRY; 3.
DR   PROSITE; PS50919; MIR; 5.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Calcium channel;
KW   Calcium transport; Calmodulin-binding; Cardiomyopathy; Coiled coil;
KW   Developmental protein; Disease variant; Ion channel; Ion transport;
KW   Ligand-gated ion channel; Membrane; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Sarcoplasmic reticulum; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..4967
FT                   /note="Ryanodine receptor 2"
FT                   /id="PRO_0000219361"
FT   TOPO_DOM        1..4281
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4282..4302
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4504..4524
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4580..4600
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4730..4750
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        4769..4789
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   INTRAMEM        4820..4829
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        4850..4870
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        4871..4967
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          110..165
FT                   /note="MIR 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          172..217
FT                   /note="MIR 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          225..280
FT                   /note="MIR 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          286..343
FT                   /note="MIR 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          351..408
FT                   /note="MIR 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          599..809
FT                   /note="B30.2/SPRY 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          853..966
FT                   /note="1"
FT   REPEAT          967..1080
FT                   /note="2"
FT   DOMAIN          1025..1222
FT                   /note="B30.2/SPRY 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   DOMAIN          1337..1562
FT                   /note="B30.2/SPRY 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          2692..2810
FT                   /note="3"
FT   REPEAT          2812..2925
FT                   /note="4"
FT   REGION          853..2925
FT                   /note="4 X approximate repeats"
FT   REGION          1856..1891
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2354..2379
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3581..3610
FT                   /note="Interaction with CALM"
FT                   /evidence="ECO:0000269|PubMed:18650434"
FT   REGION          4210..4229
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          4415..4467
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          4412..4445
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        4212..4229
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4418..4467
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         1341
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:E9Q401"
FT   MOD_RES         1869
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:B0LPN4"
FT   MOD_RES         2031
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000250|UniProtKB:E9Q401"
FT   MOD_RES         2369
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:E9Q401"
FT   MOD_RES         2697
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:B0LPN4"
FT   MOD_RES         2797
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:E9Q401"
FT   MOD_RES         2808
FT                   /note="Phosphoserine; by CaMK2D and PKA"
FT                   /evidence="ECO:0000269|PubMed:10830164,
FT                   ECO:0000269|PubMed:20056922"
FT   MOD_RES         2811
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:E9Q401"
FT   MOD_RES         2814
FT                   /note="Phosphoserine; by CaMK2D"
FT                   /evidence="ECO:0000269|PubMed:20056922"
FT   MOD_RES         2947
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:E9Q401"
FT   VAR_SEQ         3715
FT                   /note="E -> EVTGSQRSK (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_005953"
FT   VARIANT         29
FT                   /note="H -> D (found in a patient with short-coupled
FT                   polymorphic ventricular tachycardia at rest; unknown
FT                   pathological significance; no effect on cytosolic Ca(2+)
FT                   activation)"
FT                   /evidence="ECO:0000269|PubMed:25463374,
FT                   ECO:0000269|PubMed:26405799"
FT                   /id="VAR_075283"
FT   VARIANT         164
FT                   /note="P -> S (in CPVT1; dbSNP:rs764772142)"
FT                   /evidence="ECO:0000269|PubMed:15466642"
FT                   /id="VAR_044086"
FT   VARIANT         176
FT                   /note="R -> Q (in ARVD2 and CPVT1; dbSNP:rs794728708)"
FT                   /evidence="ECO:0000269|PubMed:11159936,
FT                   ECO:0000269|PubMed:12106942, ECO:0000269|PubMed:16188589"
FT                   /id="VAR_044087"
FT   VARIANT         414
FT                   /note="R -> L (in CPVT1; dbSNP:rs371121679)"
FT                   /evidence="ECO:0000269|PubMed:15466642,
FT                   ECO:0000269|PubMed:16188589"
FT                   /id="VAR_044088"
FT   VARIANT         419
FT                   /note="I -> F (in CPVT1; decreases protein stability;
FT                   dbSNP:rs1349176732)"
FT                   /evidence="ECO:0000269|PubMed:15466642,
FT                   ECO:0000269|PubMed:16188589, ECO:0000269|PubMed:25372681"
FT                   /id="VAR_044089"
FT   VARIANT         420
FT                   /note="R -> W (in CPVT1; dbSNP:rs190140598)"
FT                   /evidence="ECO:0000269|PubMed:12106942,
FT                   ECO:0000269|PubMed:15544015"
FT                   /id="VAR_044090"
FT   VARIANT         433
FT                   /note="L -> P (in ARVD2 and CPVT1; dbSNP:rs121918602)"
FT                   /evidence="ECO:0000269|PubMed:11159936,
FT                   ECO:0000269|PubMed:12106942"
FT                   /id="VAR_011395"
FT   VARIANT         466
FT                   /note="P -> A (in CPVT1; unknown pathological significance;
FT                   dbSNP:rs376612295)"
FT                   /evidence="ECO:0000269|PubMed:16188589"
FT                   /id="VAR_079513"
FT   VARIANT         507
FT                   /note="V -> I (in dbSNP:rs16835270)"
FT                   /id="VAR_044091"
FT   VARIANT         1886
FT                   /note="G -> S (in dbSNP:rs3766871)"
FT                   /id="VAR_022078"
FT   VARIANT         2246
FT                   /note="S -> L (in CPVT1; dbSNP:rs121918597)"
FT                   /evidence="ECO:0000269|PubMed:11208676,
FT                   ECO:0000269|PubMed:12093772, ECO:0000269|PubMed:15544015"
FT                   /id="VAR_011396"
FT   VARIANT         2306
FT                   /note="V -> I (in CPVT1; dbSNP:rs794728746)"
FT                   /evidence="ECO:0000269|PubMed:14571276"
FT                   /id="VAR_023694"
FT   VARIANT         2311
FT                   /note="E -> D (in CPVT1; dbSNP:rs794728747)"
FT                   /evidence="ECO:0000269|PubMed:12093772"
FT                   /id="VAR_044092"
FT   VARIANT         2328
FT                   /note="P -> S (in CPVT1; dbSNP:rs121918603)"
FT                   /evidence="ECO:0000269|PubMed:11157710"
FT                   /id="VAR_011397"
FT   VARIANT         2386
FT                   /note="N -> I (in ARVD2 and CPVT1; dbSNP:rs121918601)"
FT                   /evidence="ECO:0000269|PubMed:11159936,
FT                   ECO:0000269|PubMed:12106942"
FT                   /id="VAR_011398"
FT   VARIANT         2387
FT                   /note="A -> P (in CPVT1; dbSNP:rs794728753)"
FT                   /evidence="ECO:0000269|PubMed:15046073"
FT                   /id="VAR_044093"
FT   VARIANT         2392
FT                   /note="Y -> C (in CPVT1; dbSNP:rs772220753)"
FT                   /evidence="ECO:0000269|PubMed:12106942"
FT                   /id="VAR_044094"
FT   VARIANT         2403
FT                   /note="A -> T (in CPVT1; dbSNP:rs1456929288)"
FT                   /evidence="ECO:0000269|PubMed:15466642,
FT                   ECO:0000269|PubMed:16188589"
FT                   /id="VAR_044095"
FT   VARIANT         2474
FT                   /note="R -> S (in CPVT1; dbSNP:rs121918598)"
FT                   /evidence="ECO:0000269|PubMed:11208676,
FT                   ECO:0000269|PubMed:12093772"
FT                   /id="VAR_011399"
FT   VARIANT         2504
FT                   /note="T -> M (in ARVD2 and CPVT1; dbSNP:rs769219555)"
FT                   /evidence="ECO:0000269|PubMed:11159936,
FT                   ECO:0000269|PubMed:12106942"
FT                   /id="VAR_044096"
FT   VARIANT         2958
FT                   /note="Q -> R (in dbSNP:rs34967813)"
FT                   /evidence="ECO:0000269|PubMed:11157710"
FT                   /id="VAR_011590"
FT   VARIANT         3774
FT                   /note="Q -> L (in VACRDS; decreased function in release of
FT                   sequestered calcium ion into cytosol by sarcoplasmic
FT                   reticulum; changed ryanodine-sensitive calcium-release
FT                   channel activity; mutant channels are less resposive to
FT                   activation by caffeine and store calcium overload; affects
FT                   channel sensitivity to cytosolic and luminal calcium
FT                   activation)"
FT                   /evidence="ECO:0000269|PubMed:33536282"
FT                   /id="VAR_085649"
FT   VARIANT         3778
FT                   /note="L -> F (in CPVT1; dbSNP:rs1472508624)"
FT                   /evidence="ECO:0000269|PubMed:12093772"
FT                   /id="VAR_044097"
FT   VARIANT         3800
FT                   /note="C -> F (in CPVT1; dbSNP:rs1239093704)"
FT                   /evidence="ECO:0000269|PubMed:16188589"
FT                   /id="VAR_079514"
FT   VARIANT         3946
FT                   /note="G -> S (in CPVT1; changed ryanodine-sensitive
FT                   calcium-release channel activity; increased sensitivity to
FT                   cytosolic calcium activation; dbSNP:rs794728777)"
FT                   /evidence="ECO:0000269|PubMed:12093772,
FT                   ECO:0000269|PubMed:27733687"
FT                   /id="VAR_044098"
FT   VARIANT         4097
FT                   /note="N -> S (in CPVT1; dbSNP:rs794728784)"
FT                   /evidence="ECO:0000269|PubMed:15544015"
FT                   /id="VAR_044099"
FT   VARIANT         4104
FT                   /note="N -> K (in CPVT1; dbSNP:rs121918599)"
FT                   /evidence="ECO:0000269|PubMed:11208676,
FT                   ECO:0000269|PubMed:12093772"
FT                   /id="VAR_011400"
FT   VARIANT         4124
FT                   /note="S -> T (in CPVT1; changed ryanodine-sensitive
FT                   calcium-release channel activity; increased sensitivity to
FT                   cytosolic calcium activation; dbSNP:rs1385881911)"
FT                   /evidence="ECO:0000269|PubMed:16188589,
FT                   ECO:0000269|PubMed:27733687"
FT                   /id="VAR_079515"
FT   VARIANT         4146
FT                   /note="E -> K (in CPVT1; dbSNP:rs1349585791)"
FT                   /evidence="ECO:0000269|PubMed:15544015"
FT                   /id="VAR_044100"
FT   VARIANT         4158
FT                   /note="T -> P (in CPVT1; changed ryanodine-sensitive
FT                   calcium-release channel activity; increased sensitivity to
FT                   cytosolic calcium activation; dbSNP:rs1202962809)"
FT                   /evidence="ECO:0000269|PubMed:15544015,
FT                   ECO:0000269|PubMed:27733687"
FT                   /id="VAR_044101"
FT   VARIANT         4159
FT                   /note="Q -> P (in CPVT1; changed ryanodine-sensitive
FT                   calcium-release channel activity; increased sensitivity to
FT                   cytosolic calcium activation; dbSNP:rs1234963411)"
FT                   /evidence="ECO:0000269|PubMed:24793461,
FT                   ECO:0000269|PubMed:27733687"
FT                   /id="VAR_079516"
FT   VARIANT         4196
FT                   /note="T -> I (in VACRDS; decreased function in release of
FT                   sequestered calcium ion into cytosol by sarcoplasmic
FT                   reticulum; changed ryanodine-sensitive calcium-release
FT                   channel activity; mutant channels are less resposive to
FT                   activation by caffeine and store calcium overload; affects
FT                   channel sensitivity to cytosolic and luminal calcium
FT                   activation)"
FT                   /evidence="ECO:0000269|PubMed:33536282"
FT                   /id="VAR_085650"
FT   VARIANT         4201
FT                   /note="Q -> R (in CPVT1; dbSNP:rs121918605)"
FT                   /evidence="ECO:0000269|PubMed:11157710"
FT                   /id="VAR_011401"
FT   VARIANT         4497
FT                   /note="R -> C (in CPVT1; dbSNP:rs121918600)"
FT                   /evidence="ECO:0000269|PubMed:11208676,
FT                   ECO:0000269|PubMed:12093772, ECO:0000269|PubMed:15544015"
FT                   /id="VAR_011402"
FT   VARIANT         4499
FT                   /note="F -> C (in CPVT1; dbSNP:rs1457271141)"
FT                   /evidence="ECO:0000269|PubMed:15466642,
FT                   ECO:0000269|PubMed:16188589"
FT                   /id="VAR_044102"
FT   VARIANT         4504
FT                   /note="M -> I (in CPVT1; dbSNP:rs1323621379)"
FT                   /evidence="ECO:0000269|PubMed:15046072"
FT                   /id="VAR_044103"
FT   VARIANT         4510
FT                   /note="A -> T (in CPVT1; dbSNP:rs397516510)"
FT                   /evidence="ECO:0000269|PubMed:15466642,
FT                   ECO:0000269|PubMed:16188589"
FT                   /id="VAR_044104"
FT   VARIANT         4556
FT                   /note="A -> T (in CPVT1; dbSNP:rs189345192)"
FT                   /evidence="ECO:0000269|PubMed:16188589"
FT                   /id="VAR_079517"
FT   VARIANT         4607
FT                   /note="A -> P (in CPVT1; dbSNP:rs1359163728)"
FT                   /evidence="ECO:0000269|PubMed:15046073"
FT                   /id="VAR_044105"
FT   VARIANT         4646
FT                   /note="D -> A (in VACRDS; decreased function in release of
FT                   sequestered calcium ion into cytosol by sarcoplasmic
FT                   reticulum; changed ryanodine-sensitive calcium-release
FT                   channel activity; mutant channels are less resposive to
FT                   activation by caffeine and store calcium overload; affects
FT                   channel sensitivity to cytosolic and luminal calcium
FT                   activation)"
FT                   /evidence="ECO:0000269|PubMed:33536282"
FT                   /id="VAR_085651"
FT   VARIANT         4653
FT                   /note="V -> F (in CPVT1; dbSNP:rs121918604)"
FT                   /evidence="ECO:0000269|PubMed:11157710"
FT                   /id="VAR_011403"
FT   VARIANT         4671
FT                   /note="G -> R (in CPVT1; dbSNP:rs1188352725)"
FT                   /evidence="ECO:0000269|PubMed:15466642"
FT                   /id="VAR_044106"
FT   VARIANT         4771
FT                   /note="V -> I (in CPVT1; dbSNP:rs794728804)"
FT                   /evidence="ECO:0000269|PubMed:12093772"
FT                   /id="VAR_044107"
FT   VARIANT         4848
FT                   /note="I -> V (in CPVT1; dbSNP:rs1363298408)"
FT                   /evidence="ECO:0000269|PubMed:15466642,
FT                   ECO:0000269|PubMed:16188589"
FT                   /id="VAR_044108"
FT   VARIANT         4860
FT                   /note="A -> G (in VACRDS; decreased function in release of
FT                   sequestered calcium ion into cytosol by sarcoplasmic
FT                   reticulum; changed ryanodine-sensitive calcium-release
FT                   channel activity; diminishes the response to activation by
FT                   luminal Ca(2+) but has little effect on the sensitivity of
FT                   the channel to activation by cytosolic Ca(2+); shows
FT                   caffeine-induced Ca(2+) release but exhibits no
FT                   store-overload-induced Ca(2+) release (SOICR); HL1 cardiac
FT                   cells transfected with the G-4860 mutant displayed
FT                   attenuated SOICR activity compared to cells transfected
FT                   with wild-type RYR2; dbSNP:rs121918606)"
FT                   /evidence="ECO:0000269|PubMed:12093772,
FT                   ECO:0000269|PubMed:17984046, ECO:0000269|PubMed:33536282"
FT                   /id="VAR_044109"
FT   VARIANT         4867
FT                   /note="I -> M (in CPVT1; dbSNP:rs1218096653)"
FT                   /evidence="ECO:0000269|PubMed:12093772"
FT                   /id="VAR_044110"
FT   VARIANT         4880
FT                   /note="V -> A (in CPVT1; dbSNP:rs1242723821)"
FT                   /evidence="ECO:0000269|PubMed:15046072"
FT                   /id="VAR_044111"
FT   VARIANT         4895
FT                   /note="N -> D (in CPVT1; dbSNP:rs1185619003)"
FT                   /evidence="ECO:0000269|PubMed:12093772"
FT                   /id="VAR_044112"
FT   VARIANT         4902
FT                   /note="P -> L (in CPVT1; dbSNP:rs1475453069)"
FT                   /evidence="ECO:0000269|PubMed:14571276"
FT                   /id="VAR_023695"
FT   VARIANT         4938
FT                   /note="S -> F (in VACRDS; decreased function in release of
FT                   sequestered calcium ion into cytosol by sarcoplasmic
FT                   reticulum; changed ryanodine-sensitive calcium-release
FT                   channel activity; mutant channels are less resposive to
FT                   activation by caffeine and store calcium overload; affects
FT                   channel sensitivity to cytosolic and luminal calcium
FT                   activation)"
FT                   /evidence="ECO:0000269|PubMed:33536282"
FT                   /id="VAR_085652"
FT   VARIANT         4950
FT                   /note="E -> K (in CPVT1; dbSNP:rs886039172)"
FT                   /evidence="ECO:0000269|PubMed:12093772"
FT                   /id="VAR_044113"
FT   VARIANT         4955
FT                   /note="G -> E (probable disease-associated variant found in
FT                   a patient with intellectual disability, seizures, short
FT                   stature and severe atrial arrhythmias; dbSNP:rs1553343100)"
FT                   /evidence="ECO:0000269|PubMed:25356899"
FT                   /id="VAR_078648"
FT   VARIANT         4959
FT                   /note="R -> Q (in CPVT1; dbSNP:rs794728811)"
FT                   /evidence="ECO:0000269|PubMed:14571276,
FT                   ECO:0000269|PubMed:16188589"
FT                   /id="VAR_023696"
FT   MUTAGEN         2808
FT                   /note="S->A: Abolishes phosphorylation by PKA."
FT                   /evidence="ECO:0000269|PubMed:10830164"
FT   MUTAGEN         3946
FT                   /note="G->A: Changed ryanodine-sensitive calcium-release
FT                   channel activity characterized by increased sensitivity to
FT                   cytosolic calcium activation."
FT                   /evidence="ECO:0000269|PubMed:27733687"
FT   MUTAGEN         3978
FT                   /note="M->I: Changed ryanodine-sensitive calcium-release
FT                   channel activity characterized by increased sensitivity to
FT                   cytosolic calcium activation."
FT                   /evidence="ECO:0000269|PubMed:27733687"
FT   MUTAGEN         3995
FT                   /note="I->V: Decreased function in release of sequestered
FT                   calcium ion into cytosol by sarcoplasmic reticulum. Changed
FT                   ryanodine-sensitive calcium-release channel activity.
FT                   Mutant channels are less resposive to activation by
FT                   caffeine and store calcium overload. Affects channel
FT                   sensitivity to cytosolic and luminal calcium activation."
FT                   /evidence="ECO:0000269|PubMed:33536282"
FT   MUTAGEN         4108
FT                   /note="H->N: Changed ryanodine-sensitive calcium-release
FT                   channel activity characterized by increased sensitivity to
FT                   cytosolic calcium activation."
FT                   /evidence="ECO:0000269|PubMed:27733687"
FT   MUTAGEN         4108
FT                   /note="H->Q: Changed ryanodine-sensitive calcium-release
FT                   channel activity characterized by increased sensitivity to
FT                   cytosolic calcium activation."
FT                   /evidence="ECO:0000269|PubMed:27733687"
FT   MUTAGEN         4112
FT                   /note="D->N: Decreased function in release of sequestered
FT                   calcium ion into cytosol by sarcoplasmic reticulum. Changed
FT                   ryanodine-sensitive calcium-release channel activity.
FT                   Mutant channels are less resposive to activation by
FT                   caffeine and store calcium overload. Affects channel
FT                   sensitivity to cytosolic and luminal calcium activation."
FT                   /evidence="ECO:0000269|PubMed:33536282"
FT   MUTAGEN         4855
FT                   /note="I->M: Decreased function in release of sequestered
FT                   calcium ion into cytosol by sarcoplasmic reticulum. Changed
FT                   ryanodine-sensitive calcium-release channel activity.
FT                   Mutant channels are less resposive to activation by
FT                   caffeine and store calcium overload. Affects channel
FT                   sensitivity to cytosolic and luminal calcium activation."
FT                   /evidence="ECO:0000269|PubMed:33536282"
FT   MUTAGEN         4879
FT                   /note="Q->H: Decreased function in release of sequestered
FT                   calcium ion into cytosol by sarcoplasmic reticulum. Changed
FT                   ryanodine-sensitive calcium-release channel activity.
FT                   Mutant channels are less resposive to activation by
FT                   caffeine and store calcium overload. Affects channel
FT                   sensitivity to cytosolic and luminal calcium activation."
FT                   /evidence="ECO:0000269|PubMed:33536282"
FT   CONFLICT        1037
FT                   /note="L -> P (in Ref. 1; CAA66975 and 2; CAC18855)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2785..2789
FT                   /note="WGWRI -> RTMRT (in Ref. 1; CAA66975 and 2;
FT                   CAC18855)"
FT                   /evidence="ECO:0000305"
FT   STRAND          19..28
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          31..38
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          48..51
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   TURN            53..57
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   HELIX           63..65
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          67..73
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   TURN            108..110
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          118..127
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          129..132
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   TURN            139..141
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          145..151
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          159..166
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          180..185
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   TURN            186..188
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          191..196
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          198..208
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          212..218
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          233..238
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   TURN            239..242
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          243..246
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          250..252
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   HELIX           256..258
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          261..263
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   HELIX           265..269
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   HELIX           271..273
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          275..280
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   TURN            283..286
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          295..299
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   TURN            300..302
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          305..308
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          310..312
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          314..317
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   HELIX           319..321
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   HELIX           324..327
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          329..336
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          340..342
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   TURN            356..358
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          360..365
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   TURN            366..368
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          371..375
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          388..396
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          403..407
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   HELIX           410..437
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   HELIX           442..444
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   HELIX           449..462
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   HELIX           472..491
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   HELIX           494..506
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   STRAND          508..510
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   HELIX           511..518
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   HELIX           520..541
FT                   /evidence="ECO:0007829|PDB:4JKQ"
FT   HELIX           3584..3604
FT                   /evidence="ECO:0007829|PDB:6Y4O"
FT   HELIX           4247..4272
FT                   /evidence="ECO:0007829|PDB:7KL5"
SQ   SEQUENCE   4967 AA;  564567 MW;  44984485F8677B42 CRC64;
     MADGGEGEDE IQFLRTDDEV VLQCTATIHK EQQKLCLAAE GFGNRLCFLE STSNSKNVPP
     DLSICTFVLE QSLSVRALQE MLANTVEKSE GQVDVEKWKF MMKTAQGGGH RTLLYGHAIL
     LRHSYSGMYL CCLSTSRSST DKLAFDVGLQ EDTTGEACWW TIHPASKQRS EGEKVRVGDD
     LILVSVSSER YLHLSYGNGS LHVDAAFQQT LWSVAPISSG SEAAQGYLIG GDVLRLLHGH
     MDECLTVPSG EHGEEQRRTV HYEGGAVSVH ARSLWRLETL RVAWSGSHIR WGQPFRLRHV
     TTGKYLSLME DKNLLLMDKE KADVKSTAFT FRSSKEKLDV GVRKEVDGMG TSEIKYGDSV
     CYIQHVDTGL WLTYQSVDVK SVRMGSIQRK AIMHHEGHMD DGISLSRSQH EESRTARVIR
     STVFLFNRFI RGLDALSKKA KASTVDLPIE SVSLSLQDLI GYFHPPDEHL EHEDKQNRLR
     ALKNRQNLFQ EEGMINLVLE CIDRLHVYSS AAHFADVAGR EAGESWKSIL NSLYELLAAL
     IRGNRKNCAQ FSGSLDWLIS RLERLEASSG ILEVLHCVLV ESPEALNIIK EGHIKSIISL
     LDKHGRNHKV LDVLCSLCVC HGVAVRSNQH LICDNLLPGR DLLLQTRLVN HVSSMRPNIF
     LGVSEGSAQY KKWYYELMVD HTEPFVTAEA THLRVGWAST EGYSPYPGGG EEWGGNGVGD
     DLFSYGFDGL HLWSGCIART VSSPNQHLLR TDDVISCCLD LSAPSISFRI NGQPVQGMFE
     NFNIDGLFFP VVSFSAGIKV RFLLGGRHGE FKFLPPPGYA PCYEAVLPKE KLKVEHSREY
     KQERTYTRDL LGPTVSLTQA AFTPIPVDTS QIVLPPHLER IREKLAENIH ELWVMNKIEL
     GWQYGPVRDD NKRQHPCLVE FSKLPEQERN YNLQMSLETL KTLLALGCHV GISDEHAEDK
     VKKMKLPKNY QLTSGYKPAP MDLSFIKLTP SQEAMVDKLA ENAHNVWARD RIRQGWTYGI
     QQDVKNRRNP RLVPYTLLDD RTKKSNKDSL REAVRTLLGY GYNLEAPDQD HAARAEVCSG
     TGERFRIFRA EKTYAVKAGR WYFEFETVTA GDMRVGWSRP GCQPDQELGS DERAFAFDGF
     KAQRWHQGNE HYGRSWQAGD VVGCMVDMNE HTMMFTLNGE ILLDDSGSEL AFKDFDVGDG
     FIPVCSLGVA QVGRMNFGKD VSTLKYFTIC GLQEGYEPFA VNTNRDITMW LSKRLPQFLQ
     VPSNHEHIEV TRIDGTIDSS PCLKVTQKSF GSQNSNTDIM FYRLSMPIEC AEVFSKTVAG
     GLPGAGLFGP KNDLEDYDAD SDFEVLMKTA HGHLVPDRVD KDKEATKPEF NNHKDYAQEK
     PSRLKQRFLL RRTKPDYSTS HSARLTEDVL ADDRDDYDFL MQTSTYYYSV RIFPGQEPAN
     VWVGWITSDF HQYDTGFDLD RVRTVTVTLG DEKGKVHESI KRSNCYMVCA GESMSPGQGR
     NNNGLEIGCV VDAASGLLTF IANGKELSTY YQVEPSTKLF PAVFAQATSP NVFQFELGRI
     KNVMPLSAGL FKSEHKNPVP QCPPRLHVQF LSHVLWSRMP NQFLKVDVSR ISERQGWLVQ
     CLDPLQFMSL HIPEENRSVD ILELTEQEEL LKFHYHTLRL YSAVCALGNH RVAHALCSHV
     DEPQLLYAIE NKYMPGLLRA GYYDLLIDIH LSSYATARLM MNNEYIVPMT EETKSITLFP
     DENKKHGLPG IGLSTSLRPR MQFSSPSFVS ISNECYQYSP EFPLDILKSK TIQMLTEAVK
     EGSLHARDPV GGTTEFLFVP LIKLFYTLLI MGIFHNEDLK HILQLIEPSV FKEAATPEEE
     SDTLEKELSV DDAKLQGAGE EEAKGGKRPK EGLLQMKLPE PVKLQMCLLL QYLCDCQVRH
     RIEAIVAFSD DFVAKLQDNQ RFRYNEVMQA LNMSAALTAR KTKEFRSPPQ EQINMLLNFK
     DDKSECPCPE EIRDQLLDFH EDLMTHCGIE LDEDGSLDGN SDLTIRGRLL SLVEKVTYLK
     KKQAEKPVES DSKKSSTLQQ LISETMVRWA QESVIEDPEL VRAMFVLLHR QYDGIGGLVR
     ALPKTYTING VSVEDTINLL ASLGQIRSLL SVRMGKEEEK LMIRGLGDIM NNKVFYQHPN
     LMRALGMHET VMEVMVNVLG GGESKEITFP KMVANCCRFL CYFCRISRQN QKAMFDHLSY
     LLENSSVGLA SPAMRGSTPL DVAAASVMDN NELALALREP DLEKVVRYLA GCGLQSCQML
     VSKGYPDIGW NPVEGERYLD FLRFAVFCNG ESVEENANVV VRLLIRRPEC FGPALRGEGG
     NGLLAAMEEA IKIAEDPSRD GPSPNSGSSK TLDTEEEEDD TIHMGNAIMT FYSALIDLLG
     RCAPEMHLIH AGKGEAIRIR SILRSLIPLG DLVGVISIAF QMPTIAKDGN VVEPDMSAGF
     CPDHKAAMVL FLDRVYGIEV QDFLLHLLEV GFLPDLRAAA SLDTAALSAT DMALALNRYL
     CTAVLPLLTR CAPLFAGTEH HASLIDSLLH TVYRLSKGCS LTKAQRDSIE VCLLSICGQL
     RPSMMQHLLR RLVFDVPLLN EHAKMPLKLL TNHYERCWKY YCLPGGWGNF GAASEEELHL
     SRKLFWGIFD ALSQKKYEQE LFKLALPCLS AVAGALPPDY MESNYVSMME KQSSMDSEGN
     FNPQPVDTSN ITIPEKLEYF INKYAEHSHD KWSMDKLANG WIYGEIYSDS SKVQPLMKPY
     KLLSEKEKEI YRWPIKESLK TMLAWGWRIE RTREGDSMAL YNRTRRISQT SQVSVDAAHG
     YSPRAIDMSN VTLSRDLHAM AEMMAENYHN IWAKKKKMEL ESKGGGNHPL LVPYDTLTAK
     EKAKDREKAQ DILKFLQING YAVSRGFKDL ELDTPSIEKR FAYSFLQQLI RYVDEAHQYI
     LEFDGGSRGK GEHFPYEQEI KFFAKVVLPL IDQYFKNHRL YFLSAASRPL CSGGHASNKE
     KEMVTSLFCK LGVLVRHRIS LFGNDATSIV NCLHILGQTL DARTVMKTGL ESVKSALRAF
     LDNAAEDLEK TMENLKQGQF THTRNQPKGV TQIINYTTVA LLPMLSSLFE HIGQHQFGED
     LILEDVQVSC YRILTSLYAL GTSKSIYVER QRSALGECLA AFAGAFPVAF LETHLDKHNI
     YSIYNTKSSR ERAALSLPTN VEDVCPNIPS LEKLMEEIVE LAESGIRYTQ MPHVMEVILP
     MLCSYMSRWW EHGPENNPER AEMCCTALNS EHMNTLLGNI LKIIYNNLGI DEGAWMKRLA
     VFSQPIINKV KPQLLKTHFL PLMEKLKKKA ATVVSEEDHL KAEARGDMSE AELLILDEFT
     TLARDLYAFY PLLIRFVDYN RAKWLKEPNP EAEELFRMVA EVFIYWSKSH NFKREEQNFV
     VQNEINNMSF LITDTKSKMS KAAVSDQERK KMKRKGDRYS MQTSLIVAAL KRLLPIGLNI
     CAPGDQELIA LAKNRFSLKD TEDEVRDIIR SNIHLQGKLE DPAIRWQMAL YKDLPNRTDD
     TSDPEKTVER VLDIANVLFH LEQKSKRVGR RHYCLVEHPQ RSKKAVWHKL LSKQRKRAVV
     ACFRMAPLYN LPRHRAVNLF LQGYEKSWIE TEEHYFEDKL IEDLAKPGAE PPEEDEGTKR
     VDPLHQLILL FSRTALTEKC KLEEDFLYMA YADIMAKSCH DEEDDDGEEE VKSFEEKEME
     KQKLLYQQAR LHDRGAAEMV LQTISASKGE TGPMVAATLK LGIAILNGGN STVQQKMLDY
     LKEKKDVGFF QSLAGLMQSC SVLDLNAFER QNKAEGLGMV TEEGSGEKVL QDDEFTCDLF
     RFLQLLCEGH NSDFQNYLRT QTGNNTTVNI IISTVDYLLR VQESISDFYW YYSGKDVIDE
     QGQRNFSKAI QVAKQVFNTL TEYIQGPCTG NQQSLAHSRL WDAVVGFLHV FAHMQMKLSQ
     DSSQIELLKE LMDLQKDMVV MLLSMLEGNV VNGTIGKQMV DMLVESSNNV EMILKFFDMF
     LKLKDLTSSD TFKEYDPDGK GVISKRDFHK AMESHKHYTQ SETEFLLSCA ETDENETLDY
     EEFVKRFHEP AKDIGFNVAV LLTNLSEHMP NDTRLQTFLE LAESVLNYFQ PFLGRIEIMG
     SAKRIERVYF EISESSRTQW EKPQVKESKR QFIFDVVNEG GEKEKMELFV NFCEDTIFEM
     QLAAQISESD LNERSANKEE SEKERPEEQG PRMAFFSILT VRSALFALRY NILTLMRMLS
     LKSLKKQMKK VKKMTVKDMV TAFFSSYWSI FMTLLHFVAS VFRGFFRIIC SLLLGGSLVE
     GAKKIKVAEL LANMPDPTQD EVRGDGEEGE RKPLEAALPS EDLTDLKELT EESDLLSDIF
     GLDLKREGGQ YKLIPHNPNA GLSDLMSNPV PMPEVQEKFQ EQKAKEEEKE EKEETKSEPE
     KAEGEDGEKE EKAKEDKGKQ KLRQLHTHRY GEPEVPESAF WKKIIAYQQK LLNYFARNFY
     NMRMLALFVA FAINFILLFY KVSTSSVVEG KELPTRSSSE NAKVTSLDSS SHRIIAVHYV
     LEESSGYMEP TLRILAILHT VISFFCIIGY YCLKVPLVIF KREKEVARKL EFDGLYITEQ
     PSEDDIKGQW DRLVINTQSF PNNYWDKFVK RKVMDKYGEF YGRDRISELL GMDKAALDFS
     DAREKKKPKK DSSLSAVLNS IDVKYQMWKL GVVFTDNSFL YLAWYMTMSV LGHYNNFFFA
     AHLLDIAMGF KTLRTILSSV THNGKQLVLT VGLLAVVVYL YTVVAFNFFR KFYNKSEDGD
     TPDMKCDDML TCYMFHMYVG VRAGGGIGDE IEDPAGDEYE IYRIIFDITF FFFVIVILLA
     IIQGLIIDAF GELRDQQEQV KEDMETKCFI CGIGNDYFDT VPHGFETHTL QEHNLANYLF
     FLMYLINKDE TEHTGQESYV WKMYQERCWE FFPAGDCFRK QYEDQLN
//
